FitLife Brands vs Niagen Bioscience
FTLF and NAGE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FTLF and NAGE compare
Niagen Bioscience is the larger company, worth 2.1 times as much as FitLife Brands ($163M against $79.6M).
On earnings, Niagen Bioscience is cheaper: it trades at 17.2× trailing earnings, against 44.6× for FitLife Brands.
Niagen Bioscience keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with 1.9% at FitLife Brands.
Niagen Bioscience scores higher on the StockData Score (14 against 4 for FitLife Brands), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FTLF | NAGE |
|---|---|---|
| Size and price | ||
| Market cap | $79.6M | $163M |
| Share price | $8.48 | $2.06 |
| Change, 1 year | −55.3% | −71.2% |
| Change, 5 years | 38.3% | −61.7% |
| Beta (5Y) | 0.28 | 1.05 |
| Employees | 39 | 117 |
| StockData Score | ||
| Total score | 4 | 14 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 44.6× | 17.2× (better) |
| P/S | 0.8× (better) | 1.3× |
| P/B | 1.7× (better) | 2.0× |
| EV/EBITDA | 17.9× (better) | 19.7× |
| P/FCF | 7.9× | – |
| FCF yield | 12.6% | – |
| Fair value | $7.13 | $2.46 |
| Margin of safety | −18.9% | 16.1% (better) |
| Growth | ||
| Revenue growth (TTM) | – | −1.9% |
| Revenue growth, 5Y average | −6.3% | 16.9% (better) |
| Net income growth (TTM) | – | −49.9% |
| EPS growth (TTM) | – | −50.0% |
| EPS growth, 5Y average | −27.1% | – |
| Profitability | ||
| Gross margin | 12.3% | 63.9% (better) |
| Operating margin | 3.8% | 3.9% (better) |
| Net margin | 1.9% | 8.4% (better) |
| FCF margin | 9.9% | – |
| Return on equity | 4.4% | 13.3% (better) |
| Return on invested capital | 6.1% | 44.3% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 3.4× | – |
| Current ratio | 1.46 | 5.93 (better) |
| Altman Z-score | 2.30 | 3.98 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.3% |
| Shareholder yield | 0.00% | 3.3% (better) |
| Ownership | ||
| Held by institutions | 6.8% | 40.4% |
| Held by insiders | 59.1% | 5.1% |
| Insider net buying, 12 months | $74.5K (better) | $0 |
| Short interest, % of float | 1.7% | 5.8% |
Go deeper
- FTLF stock overview
- FTLF income statement
- FTLF valuation and score
- NAGE stock overview
- NAGE income statement
- NAGE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.